Abstract
Objectives: To develop and test a new instrument (EFESO Questionnaire) to measure satisfaction with controlled ovarian stimulation (COS) treatment.
Methods: Literature review and focus groups with clinical experts provided content for the questionnaire. A preliminary version was pilot tested in 10 women to assess comprehension and relevance. The final version was administered to 606 women receiving COS. Feasibility, reliability and validity were tested by calculating the proportion of patients completing all items, by calculating Cronbach’s alpha for the overall score, and by investigating whether the instrument discriminated between patients classified according to the level of overall satisfaction and response to treatment. Factor analysis was performed.
Results: The final questionnaire consisted of 17 items. 91.7% of patients completed all of the items. Cronbach’s alpha was 0.93, indicating excellent reliability, and the instrument was capable of discriminating between patients categorized by responses to the question on overall satisfaction with treatment and by their response to treatment. Factor analysis showed the instrument to be unidimensional.
Conclusions: The EFESO questionnaire is feasible, reliable and valid for the measurement of satisfaction with treatment in patients receiving COS treatment.
Acknowledgements
The authors would like to thank all of the clinicians and nurses who participated in the study and who comprised the Spanish Collaborative Group.
Measuring satisfaction with treatment is useful in explaining why patients persist or not with treatments and in revealing aspects of treatment which are highly or poorly rated by patients. However, there is no instrument currently available to measure women’s satisfaction with ovarian stimulation treatment.
Current knowledge on this subject
A new measure of women’s satisfaction with ovarian stimulation treatment (the EFESO questionnaire) has been developed and tested following the recommended procedures. It has been shown to be feasible, reliable and valid for use in a large sample of women receiving COS treatment.
Further testing is required to determine whether it discriminates well between relevant groups and to test whether it is responsive to changes in the levels of patient satisfaction over time.